Skip to main content
Get the Weekly ESG Brief

AstraZeneca

A5NYSETrackedESG Rated: 1/2 ProvidersHealth CareDiversifiedSustainalytics: 23.1 · Medium

Market Quote Unavailable · Potential Inactive / Delisted Ticker

Public exchange feeds are not currently returning active trading data for AstraZeneca (A5). This company may be delisted, bankrupt, acquired, or halted. To preserve data integrity, prices are never displayed as $0.00. Sourced ESG ratings and sustainability disclosures remain cataloged below.

Coverage
Rated universe Carries an MSCI or Sustainalytics observation.
ESG profile reviewed
Last editorial update to this profile.
Quote
Market data unavailableObservation time is shown beside the price.
Methodology
How we rateProvider ratings are shown separately, never blended.

Market overview

Market data unavailable

Massive Stock Widgets has not returned a current, verifiable snapshot for AstraZeneca (nyse:A5). Check again later.

Company Profile & Business Model Overview

AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company. Q2 2025 Revenue: $14.46B (+11.74% YoY), Annual Revenue: $56.5B (+15% YoY). Key segments: Oncology (40%), Cardiovascular (25%), Rare Disease (17%), Respiratory (15%). Employees: 94,300. Strong ESG commitment with sustainable operations and global medicine access programs.

Sustainability Strengths & Catalysts (Pros)

  • Exceptional ESG Recognition: Triple TIME recognition as World's Best, Most Sustainable, and Best in Sustainable Growth companies validates comprehensive ESG leadership rare in pharmaceuticals.
  • Strong Financial Fundamentals: $55 billion revenue with attractive 14.52x P/E ratio and $218 billion market cap positions AstraZeneca among global pharma leaders with growth potential.
  • Climate Leadership Success: 95% renewable electricity usage and 17.5% energy reduction exceeding targets demonstrates operational excellence in environmental management.

Material Risks & Governance Concerns (Cons)

  • Stock Underperformance: Share price declined 15.09% over past year, underperforming FTSE All Share Index by 17.46%, indicating market concerns despite strong fundamentals.
  • Scope 3 Emissions Challenge: 18.6% increase in supply chain emissions from 2019 baseline highlights difficulty achieving ambitious 50% reduction target by 2030.

Related ESG Peer Equities

Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.

Explore Health Care Peers →

Profile →
Profile →
Profile →
Profile →

ESG & Sustainability Rating Breakdown

MSCI and Sustainalytics ratings shown side by side, never blended into a single score.

Third-party ratings

MSCI ESG Rating

N/A
Sustainalytics Risk Score

23.1

MediumScore date not recorded

Data integrity and methodology

MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.

FAQ

Frequently Asked Questions

Direct answers on sustainability scores, risk methodologies, and peer rankings.

What is AstraZeneca (A5)'s ESG rating and sustainability score?

AstraZeneca (A5) carries a Sustainalytics ESG Risk Score of 23.1, measuring unmanaged corporate ESG risk on a scale of 0 to 50+.

Is AstraZeneca considered an ESG leader or laggard in Health Care?

Independent benchmark status for AstraZeneca is evaluated relative to Health Care peers once third-party coverage publishes official methodology scores.

What are the main ESG risks and controversies for AstraZeneca?

Key material risks for AstraZeneca include: Stock Underperformance: Share price declined 15.09% over past year, underperforming FTSE All Share Index by 17.46%, indicating market concerns despite strong fundamentals.; Scope 3 Emissions Challenge: 18.6% increase in supply chain emissions from 2019 baseline highlights difficulty achieving ambitious 50% reduction target by 2030.. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.

How does The Impact Investor evaluate ESG stock profiles?

The Impact Investor presents third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.